IDEX Corp
IEX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$345.00 | Phzp | Qllwjljcm |
Idex Earnings: Another Guidance Cut Due to Health and Science Technologies Inventory Correction
Narrow-moat-rated Idex reported solid second-quarter results, including a 3% year-over-year organic sales increase, but lowered its full-year guidance for the second time this year due to softness in the health and science technologies segment. We’ve trimmed our fair value estimate to $217 per share from $221 to reflect our slightly more muted near-term revenue growth and operating margin projections, partially offset by the time value of money.